Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [¹⁸F]THK5351 uptake in progressive supranuclear palsy.

ABSTRACT:

Background

[¹⁸F]THK5351 is a tau positron emission tomography tracer that has shown promise in quantifying tau distribution in tauopathies such as Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). However, the interpretation of [¹⁸F]THK5351 uptake has been shown to be confounded by high monoamine oxidase B (MAO-B) availability across the brain in AD.

Objectives

To test the hypothesis that the MAO-B inhibitor, rasagiline reduces [¹⁸F]THK5351 uptake in PSP.

Methods

Six individuals (4: PSP; 2: cognitively unimpaired, CU) underwent [¹⁸F]THK5351 and [¹⁸F]AZD4694 to quantify baseline tau and amyloid deposition, respectively. Following a 10-day course of 1 mg rasagiline, all participants received a post-

SUBMITTER: Ng KP 

PROVIDER: S-EPMC6889764 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature